• 1. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Hydroxy Gliclazide: A Comprehensive Overview of Its Chemical Profile and Therapeutic Applications

Hydroxy Gliclazide (CAS no. 87368-00-1) is a pharmacologically significant compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal biology. This compound, a derivative of Gliclazide, is primarily recognized for its role as an antihyperglycemic agent, making it a crucial component in the management of type 2 diabetes mellitus. The introduction of Hydroxy Gliclazide into therapeutic regimens has been accompanied by extensive research aimed at elucidating its mechanisms of action, pharmacokinetic properties, and clinical efficacy.

The chemical structure of Hydroxy Gliclazide (CAS no. 87368-00-1) exhibits a hydroxyl group at a strategic position, which contributes to its unique pharmacological profile compared to its parent compound, Gliclazide. This modification enhances its binding affinity to the mitochondrial ATP-sensitive potassium channels in pancreatic beta cells, thereby facilitating insulin secretion. The precise arrangement of functional groups in Hydroxy Gliclazide not only influences its metabolic stability but also determines its bioavailability and therapeutic efficacy.

Recent advancements in computational chemistry and molecular modeling have provided deeper insights into the interactions between Hydroxy Gliclazide and biological targets. Studies employing high-resolution crystallography have revealed that the hydroxyl group in Hydroxy Gliclazide plays a critical role in stabilizing the compound's binding to the sulfonylurea receptor (SUR1). This interaction is pivotal for the activation of potassium channels, leading to increased insulin release. Such structural insights have paved the way for the development of more potent and selective derivatives of Gliclazide, including Hydroxy Gliclazide.

The pharmacokinetic behavior of Hydroxy Gliclazide has been thoroughly investigated in both preclinical and clinical settings. Unlike its parent compound, Hydroxy Gliclazide exhibits a longer half-life, which allows for less frequent dosing while maintaining therapeutic levels. This property is particularly advantageous for patients who require continuous blood glucose control. Additionally, studies have shown that Hydroxy Gliclazide undergoes minimal metabolism by cytochrome P450 enzymes, reducing the risk of drug-drug interactions commonly observed with other antihyperglycemic agents.

Clinical trials have demonstrated that Hydroxy Gliclazide is effective in lowering blood glucose levels in patients with type 2 diabetes mellitus without causing significant hypoglycemia when used as monotherapy or in combination with other antidiabetic agents. The compound's ability to enhance insulin secretion while maintaining glycemic control makes it a valuable addition to existing therapeutic strategies. Furthermore, its favorable safety profile has been confirmed in long-term studies, where it was shown to have minimal adverse effects on liver or kidney function.

The development of novel drug delivery systems has further enhanced the therapeutic potential of Hydroxy Gliclazide (CAS no. 87368-00-1). Advanced formulations such as extended-release tablets and transdermal patches have been designed to provide sustained release profiles, improving patient compliance and reducing the incidence of hyperglycemia episodes. These innovations have been supported by preclinical studies demonstrating improved pharmacokinetic profiles and enhanced therapeutic outcomes.

Emerging research has also explored the potential applications of Hydroxy Gliclazide beyond its traditional use in diabetes management. Studies suggest that the compound may possess additional benefits, such as anti-inflammatory and antioxidant properties, which could be relevant in the context of metabolic syndrome and related complications. While these findings are still under investigation, they highlight the multifaceted pharmacological potential of Hydroxy Gliclazide.

The synthesis and characterization of Hydroxy Gliclazide (CAS no. 87368-00-1) have been refined through modern synthetic methodologies, ensuring high purity and yield. Techniques such as chiral resolution and crystallization have been employed to optimize the compound's quality for pharmaceutical use. These advancements underscore the importance of rigorous synthetic chemistry in developing effective therapeutics for chronic diseases like diabetes.

In conclusion, Hydroxy Gliclazide represents a significant advancement in antihyperglycemic therapy due to its potent insulinotropic effects, favorable pharmacokinetic profile, and minimal adverse effects. The integration of cutting-edge research methodologies has enhanced our understanding of its mechanisms of action and therapeutic applications. As further research continues to uncover new possibilities for this compound, it is poised to remain a cornerstone in the management of type 2 diabetes mellitus.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)